Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

Treatment with an agonist anti-OX40 antibody (aOX40) boosts anti-tumor immunity by providing costimulation and driving effector T cell responses. However, tumor-induced immune suppression contributes significantly to poor response rates to aOX40 therapy, thus combining aOX40 with other agents that r...

Descripción completa

Detalles Bibliográficos
Autores principales: Sturgill, Elizabeth R., Rolig, Annah S., Linch, Stefanie N., Mick, Courtney, Kasiewicz, Melissa J., Sun, Zhaoyu, Traber, Peter G., Shlevin, Harold, Redmond, William L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927986/
https://www.ncbi.nlm.nih.gov/pubmed/33717655
http://dx.doi.org/10.1080/2162402X.2021.1892265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927986/
https://www.ncbi.nlm.nih.gov/pubmed/33717655
http://dx.doi.org/10.1080/2162402X.2021.1892265

Ejemplares similares